TY - JOUR
T1 - Assessment of Bone Marrow Involvement in Extranodal NK/T-Cell Lymphoma
T2 - Positron Emission Tomography versus Bone Marrow Biopsy, and the Significance of Minimal Involvement by EBV+ Cells (KROG 18-09)
AU - Lee, Tae Hoon
AU - Kim, Hyun Ju
AU - Lee, Jong Hoon
AU - Lee, Jeongshim
AU - Kim, Jin Hee
AU - Oh, Dongryul
AU - Keun-Yong, Eom
N1 - Publisher Copyright:
2024by theKoreanCancerAssociation.
PY - 2024/4
Y1 - 2024/4
N2 - Purpose This study aims to investigate the diagnostic significance of positron emission tomography/computed tomography (PET/ CT) in assessing bone marrow (BM) involvement through a comparison of PET/CT findings with BM biopsy in extranodal natural killer /T-cell lymphoma. Materials and Methods The medical records of 193 patients were retrospectively reviewed. Patients were categorized as having early-stage (PET-ES) or advanced-stage (PET-AS) disease based on PET/CT results. The BM involvement was classified into three groups according to BM biopsy: gross BM involvement, minimal BM involvement (defined as the presence of a limited number of Epstein-Barr virus–positive cells in BM), and no involvement. Calculations of the accuracy of PET/CT in detecting BM involvement and analysis of the clinical outcomes (progression-free survival [PFS] and overall survival [OS]) according to the BM biopsy status were performed. Results PET/CT exhibited a sensitivity of 64.7% and a specificity of 96.0% in detecting gross BM involvement. For detecting any (both gross and minimal) BM involvement, the sensitivity was 30.4%, while the specificity was 99.0%. Only one patient (0.7%) demonstrated gross BM involvement among the PET-ES group. Survival outcomes of the PET-ES group with minimal BM involvement (3-year PFS, 55.6%; OS, 77.0%) were closer to those of the PET-ES group with no BM involvement (3-year PFS, 62.2%; OS, 80.6%) than to those of the PET-AS group (3-year PFS, 20.1%; OS, 29.9%). Conclusion PET/CT exhibits high specificity, but moderate and low sensitivity in detecting gross and minimal BM involvement, respectively. The clinical significance of minimal BM involvement for patients in the PET-ES group may be limited.
AB - Purpose This study aims to investigate the diagnostic significance of positron emission tomography/computed tomography (PET/ CT) in assessing bone marrow (BM) involvement through a comparison of PET/CT findings with BM biopsy in extranodal natural killer /T-cell lymphoma. Materials and Methods The medical records of 193 patients were retrospectively reviewed. Patients were categorized as having early-stage (PET-ES) or advanced-stage (PET-AS) disease based on PET/CT results. The BM involvement was classified into three groups according to BM biopsy: gross BM involvement, minimal BM involvement (defined as the presence of a limited number of Epstein-Barr virus–positive cells in BM), and no involvement. Calculations of the accuracy of PET/CT in detecting BM involvement and analysis of the clinical outcomes (progression-free survival [PFS] and overall survival [OS]) according to the BM biopsy status were performed. Results PET/CT exhibited a sensitivity of 64.7% and a specificity of 96.0% in detecting gross BM involvement. For detecting any (both gross and minimal) BM involvement, the sensitivity was 30.4%, while the specificity was 99.0%. Only one patient (0.7%) demonstrated gross BM involvement among the PET-ES group. Survival outcomes of the PET-ES group with minimal BM involvement (3-year PFS, 55.6%; OS, 77.0%) were closer to those of the PET-ES group with no BM involvement (3-year PFS, 62.2%; OS, 80.6%) than to those of the PET-AS group (3-year PFS, 20.1%; OS, 29.9%). Conclusion PET/CT exhibits high specificity, but moderate and low sensitivity in detecting gross and minimal BM involvement, respectively. The clinical significance of minimal BM involvement for patients in the PET-ES group may be limited.
KW - Bone marrow
KW - Key words NK/T-cell lymphoma
KW - Minimal involvement
KW - Positron emission tomography
UR - https://www.scopus.com/pages/publications/85190323299
U2 - 10.4143/crt.2023.1049
DO - 10.4143/crt.2023.1049
M3 - Article
C2 - 38097921
AN - SCOPUS:85190323299
SN - 1598-2998
VL - 56
SP - 688
EP - 696
JO - Cancer Research and Treatment
JF - Cancer Research and Treatment
IS - 2
ER -